Innovative T Cell-Based Immunotherapies Facility

Project Scope:

Marker, a clinical-stage immuno-oncology company specializing in the development and commercialization of novel T cell-based immunotherapies and innovative peptide-based vaccines, needed facility to manufacture two products simultaneously for Phase II and III trials. The GBA team was selected to perform design-build services for the process areas and host facility modifications required to house G-CON PODs and perform production and laboratory operations. This included the auxiliary areas to support the process such as administrative areas, emergency generation, chillers, lab and storage spaces, lockers and gowning areas, and cryo storage and kitting areas. Low first cost was the primary driver.

Low first cost was the primary driver. The initial phase was a single 1,700-SF cleanroom consisting of three subPODs joined on-site to form one larger POD. The site was designed to easily accommodate up to six additional process suites mirrored along a central CNC corridor, scaling the facility as revenue and demand grow.